BIIB logo

BIIB
Biogen Inc

18,634
Mkt Cap
$34.3B
Volume
3.4M
52W High
$202.41
52W Low
$110.04
PE Ratio
22.85
BIIB Fundamentals
Price
$198.60
Prev Close
$185.36
Open
$187.01
50D MA
$177.52
Beta
0.63
Avg. Volume
1.56M
EPS (Annual)
$8.79
P/B
1.62
Rev/Employee
$1.27M
Loading...
Loading...
Poll

Earnings Recap

• Reported GAAP EPS of -$0.33 down -118.03% YoY • Reported revenue of $2.28B down -7.14% YoY • Biogen expects full year 2026 Non-GAAP diluted EPS to be between $15.25 and $16.25. Total revenue is anticipated to decline by a mid-single digit percentage compared to full year 2025.

Bullish

Biogen's growth products showed strong Q4 2025 commercial execution, while pipeline advancements like LEQEMBI IQLIK's Priority Review and litifilimab's Breakthrough Therapy Designation highlight future value.

Bearish

Biogen faces declining revenue outlook for 2026 due to MS product erosion and reported negative GAAP EPS in Q4 2025. Increased IPR&D and litigation-related costs also pressured profitability.

Latest BIIB News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.